INCY Latest Press Releases

-- November 10, 2026 --

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer Business Wire 7:00 AM

-- November 4, 2026 --

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026 Business Wire 9:00 AM

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

-- October 29, 2026 --

Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates Business Wire 7:00 AM

-- October 26, 2026 --

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 Business Wire 9:45 AM

-- October 24, 2026 --

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer Business Wire 7:01 AM

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer Business Wire 7:00 AM

-- October 18, 2026 --

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Business Wire 6:05 PM

-- October 8, 2026 --

Incyte to Report Third Quarter Financial Results Business Wire 8:00 AM

-- October 6, 2026 --

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO in Brazil Globe Newswire 7:35 AM

-- September 28, 2026 --

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary PRNewswire 9:03 AM

-- September 25, 2026 --

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva Business Wire 7:00 PM

-- September 22, 2026 --

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio Business Wire 8:30 AM

-- September 20, 2026 --

Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura) in Australia PRNewswire 4:00 PM

-- September 1, 2026 --

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

-- August 27, 2026 --

Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI (tafasitamab) in Brazil Globe Newswire 6:00 PM

-- August 7, 2026 --

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- August 2, 2026 --

New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS PRNewswire 10:01 AM

-- July 29, 2026 --

Opzelura (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis Business Wire 6:00 AM

-- July 28, 2026 --

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates Business Wire 7:00 AM

-- July 20, 2026 --

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology PRNewswire 8:00 AM

-- July 17, 2026 --

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers Business Wire 1:10 PM

-- July 13, 2026 --

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types Business Wire 4:00 AM

-- July 8, 2026 --

Incyte to Report Second Quarter Financial Results Business Wire 8:00 AM

-- July 6, 2026 --

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio Business Wire 8:39 AM

-- June 26, 2026 --

Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress Business Wire 9:00 AM

Incyte Announces Positive CHMP Opinion for Opzelura (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis Business Wire 7:30 AM

-- June 19, 2026 --

Incyte Japan Announces Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Business Wire 2:47 AM